MB66
/ Mapp Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 02, 2020
[VIRTUAL] PHASE I PLACEBO-CONTROLED SAFETY, PK, AND PD STUDY OF MB66 ANTI-HIV AND ANTI-HSV FILM
(CROI 2020)
- "Monoclonal antibodies(mAbs)show promise as multipurpose prevention technology.The MB66 intravaginal film contains 10 mg each of anti-HIV(VRC01) and anti-HSV(HSV8) mAbs to provide protection against two incurable viral infections. Repeated doses of MB66 film was safe and tolerated.Significant HIV-1 and HSV-2 neutralization (ex vivo) was observed at 24 hrs,7 films. Antibody levels in vagina had concentrations consistent with protection for up to 24 hrs."
Clinical • P1 data
1 to 1
Of
1
Go to page
1